Clorox Company (CLX) Financial Statements

Clorox's financial health presents a classic case of quality metrics being offset by significant challenges. On the quality side, the company demonstrates strong profitability with an operating margin of 18.1% and a profit margin of 11.2%. The free cash flow yield of 6.0% is favourable and indicates solid cash generation, which supports its substantial 4.71% dividend yield. The Return on Equity (ROE) of 235.2% is exceptionally high, far exceeding the framework's 15-20% benchmark for a high ROIC, though this figure is likely inflated by the company's high financial leverage. This leverage is the primary concern. The Debt/Equity ratio of approximately 9.0 is extremely high and indicates a balance sheet under significant strain, failing the framework's check for a substantial net cash position. Growth is also unfavourable, with revenue declining 0.8% year-over-year, which does not meet the framework's criterion for consistent, double-digit growth. The lack of gross margin data limits a full assessment of core profitability trends. Overall, Clorox shows the hallmarks of a mature, cash-generative business but is burdened by debt and lacks organic growth, placing it in an 'Adequate' to 'Unfavourable' range on the Quality Indicators scorecard when considering the weak balance sheet and growth metrics. Analysis based on data as of 2024-05-15.